First-Line Treatment for Akathisia
For antipsychotic-induced akathisia, the first-line treatment is dose reduction of the offending antipsychotic when clinically feasible, followed by propranolol (10-30 mg two to three times daily) as the primary pharmacological intervention 1.
Treatment Algorithm
Step 1: Immediate Management
- Reduce the antipsychotic dose if positive symptoms are adequately controlled and the patient is within the therapeutic range 1
- This is the most direct intervention and should be attempted first when safe to do so
Step 2: Switch Antipsychotic (if dose reduction insufficient)
- Switch to quetiapine or olanzapine, which have lower akathisia liability 1
- From the dose-response evidence, sertindole and quetiapine carry negligible akathisia risk across examined doses, while most other antipsychotics show dose-dependent increases in akathisia risk 2
Step 3: Adjunctive Pharmacological Treatment
If dose reduction and switching are not viable options:
Primary option: Propranolol
- Dose: 10 mg up to 30 mg, two to three times daily 1
- Most consistently effective treatment with the strongest evidence base 3
- Contraindications: asthma, bradycardia, orthostatic hypotension 4
Alternative first-line options when propranolol is contraindicated or ineffective:
Benzodiazepines - Ranked highest in comparative efficacy (P-score 0.8186) 5, particularly useful for subjective distress 3
Low-dose mirtazapine (7.5-15 mg once daily) - Compelling evidence for efficacy through 5-HT2A antagonism 4, 6, especially valuable in treatment-resistant cases
Important Clinical Considerations
Guideline-based hierarchy: The 2025 INTEGRATE guidelines explicitly recommend propranolol as the adjunctive treatment, with dose reduction and switching to quetiapine/olanzapine as primary strategies 1. This represents the most current, high-quality guidance available.
Evidence quality: While propranolol is considered first-line, the 2024 network meta-analysis found benzodiazepines ranked highest in comparative efficacy, followed by beta-blockers 5. However, guidelines prioritize propranolol due to its established safety profile and lack of abuse potential.
Common pitfalls to avoid:
- Do not use anticholinergics as first-line unless parkinsonian symptoms coexist 7
- Avoid antipsychotic polypharmacy, which increases akathisia risk 8
- Do not continue escalating antipsychotic doses in the presence of akathisia, as most antipsychotics show dose-dependent akathisia risk 2
Treatment duration: The evidence does not provide clear guidance on duration of adjuvant medication use, warranting cautious prescribing and regular reassessment 8.